Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment

go back to reference Waldmann TA, Chen J (2017) Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy. Annu Rev Immunol 35:533–550CrossRefPubMed Waldmann TA, Chen J (2017) Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy. Annu Rev Immunol 35:533–550CrossRefPubMed

go back to reference Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7(9):673–683CrossRefPubMed Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7(9):673–683CrossRefPubMed

go back to reference Vannucchi AM, Harrison CN (2017) Emerging treatments for classical myeloproliferative neoplasms. Blood 129(6):693–703CrossRefPubMed Vannucchi AM, Harrison CN (2017) Emerging treatments for classical myeloproliferative neoplasms. Blood 129(6):693–703CrossRefPubMed

go back to reference Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062–2068CrossRefPubMedPubMedCentral Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062–2068CrossRefPubMedPubMedCentral

go back to reference McLornan DP, Khan AA, Harrison CN (2015) Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep 10(4):370–379CrossRefPubMed McLornan DP, Khan AA, Harrison CN (2015) Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep 10(4):370–379CrossRefPubMed

go back to reference Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL (2008) HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 135(4):1192–1199CrossRefPubMed Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL (2008) HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 135(4):1192–1199CrossRefPubMed

go back to reference Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF (2014) Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32(33):3736–3743CrossRefPubMed Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF (2014) Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32(33):3736–3743CrossRefPubMed

go back to reference Lai CL, Ratziu V, Yuen MF, Poynard T (2003) Viral hepatitis B. Lancet 362(9401):2089–2094CrossRef Lai CL, Ratziu V, Yuen MF, Poynard T (2003) Viral hepatitis B. Lancet 362(9401):2089–2094CrossRef

go back to reference Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G (2014) Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28(1):225–227CrossRefPubMed Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G (2014) Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28(1):225–227CrossRefPubMed

go back to reference Shen CH, Hwang CE, Chen YY, Chen CC (2014) Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 93(6):1075–1076CrossRefPubMed Shen CH, Hwang CE, Chen YY, Chen CC (2014) Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 93(6):1075–1076CrossRefPubMed

go back to reference Kirito K, Sakamoto M, Enomoto N (2016) Elevation of the hepatitis B virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med 55(10):1341–1344CrossRefPubMed Kirito K, Sakamoto M, Enomoto N (2016) Elevation of the hepatitis B virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med 55(10):1341–1344CrossRefPubMed

go back to reference Perricone G, Vinci M, Pungolino E (2017) Occult hepatitis B infection reactivation after ruxolitinib therapy. Dig Liver Dis 49(6):719CrossRefPubMed Perricone G, Vinci M, Pungolino E (2017) Occult hepatitis B infection reactivation after ruxolitinib therapy. Dig Liver Dis 49(6):719CrossRefPubMed

go back to reference Hwang JP, Lok AS (2014) Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 11(4):209–219CrossRefPubMed Hwang JP, Lok AS (2014) Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 11(4):209–219CrossRefPubMed

go back to reference Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lau EHY, Cheung KS, Lie AKW, Lai CL, Kwong YL, Yuen MF (2017) Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology 65(5):1451–1461CrossRefPubMed Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lau EHY, Cheung KS, Lie AKW, Lai CL, Kwong YL, Yuen MF (2017) Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology 65(5):1451–1461CrossRefPubMed